Literature DB >> 9167009

A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.

D J Wood1, A B Heath, G F Kersten, T Hazendonk, M Lantinga, E C Beuvery.   

Abstract

Assays of the potency of inactivated poliovirus vaccine require the use of an appropriate reference reagent. Preparation 91/574 was shown by international collaborative study to be suitable for determination of antigenic content and immunogenicity of inactivated poliovirus vaccines by in vitro and in vivo assays, respectively. The reagent is a trivalent blend of formaldehyde-inactivated monovalent pools of poliovirus type 1 (Mahoney) poliovirus type 2 (MEF-1) and poliovirus type 3 (Saukett). Studies by antigen-capture ELISA showed that the component monovalent pools contained high titres of D antigen and trace amounts of C antigen. Sucrose gradient analysis showed that the D antigenicity was almost exclusively associated with 150S virus particles. Low levels of procapsids (75S particles with D antigenicity) were detected in the type 1 and 2 monovalent pools. The profile of intact virions and procapsids in 91/574 in sucrose gradients was very similar to PU78-02, a previously used inactivated trivalent poliovirus vaccine reference. The World Health Organization (WHO) Expert Committee on Biological Standardization at its 1994 meeting established preparation 91/574 as the 2nd WHO international Reference Reagent for poliomyelitis vaccine (inactivated). A potency of 430, 95, 285 D antigen units per ml was assigned to poliovirus type 1, 2 and 3, respectively. A separate aliquot of this preparation, established by the European Pharmacopeia Commission as a Biological Reference Preparation, has an identical assigned titre. The 2nd WHO International Reference Reagent 91/574 is intended for calibration of secondary reference reagents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167009     DOI: 10.1006/biol.1996.0060

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence.

Authors:  Ira Berkower; Angelo Spadaccini; Hong Chen; Danah Al-Awadi; Jacqueline Muller; Yamei Gao; Dino Feigelstock; Konstantin Virnik; Yisheng Ni
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

Review 2.  Challenges to licensure of enterovirus 71 vaccines.

Authors:  Min-Shi Lee; Fan-Chen Tseng; Jen-Ren Wang; Chia-Yu Chi; Pele Chong; Ih-Jen Su
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28

3.  Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development.

Authors:  Min-Yuan Chia; Wan-Yu Chung; Pai-Shan Chiang; Yeh-Sheng Chien; Mei-Shang Ho; Min-Shi Lee
Journal:  PLoS Negl Trop Dis       Date:  2014-07-24

4.  Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.

Authors:  Woo-Jin Shin; Daiki Hara; Francisca Gbormittah; Hana Chang; Byeong S Chang; Jae U Jung
Journal:  MBio       Date:  2018-11-27       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.